Bristol-Myers Squibb: Crohn Disease trials

The registry lists 16 Crohn Disease studies with Bristol-Myers Squibb as lead sponsor. 0 are open to participants now and 11 have results posted.

Phase 1 1Phase 2 7Phase 3 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional TherapyTerminatedNCT05470985Phase 2/3Results posted
• A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative ColitisCompletedNCT04877990Phase 2Results posted
• An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's DiseaseTerminatedNCT03599622Phase 2Results posted
• An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's DiseaseTerminatedNCT03467958Phase 3Results posted
• A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's DiseaseTerminatedNCT03464097Phase 3Results posted
• Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's DiseaseCompletedNCT03440385Phase 3Results posted
• Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's DiseaseTerminatedNCT03440372Phase 3Results posted
• A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's DiseaseTerminatedNCT02641392Phase 3Results posted
• Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's DiseaseTerminatedNCT02596893Phase 3Results posted
• Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's DiseaseCompletedNCT02531113Phase 2Results posted
• A Study of Abatacept in Patients With Active Crohn's DiseaseTerminatedNCT00406653Phase 3Results posted
• A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's DiseaseWithdrawnNCT02974322Phase 3
• Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's DiseaseTerminatedNCT02685683Phase 2
• A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's DiseaseCompletedNCT02367183Phase 1
• Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's DiseaseCompletedNCT01466374Phase 2
• A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's DiseaseCompletedNCT00446433Phase 2